Publication details

EU-OPENSCREEN: A Novel Collaborative Approach to Facilitate Chemical Biology

Authors

BRENNECKE Philip RASINA Dace AUBI Oscar HERZOG Katja LANDSKRON Johannes CAUTAIN Bastien VICENTE Francisca QUINTANA Jordi MESTRES Jordi STECHMANN Bahne ELLINGER Bernhard BREA Jose KOLANOWSKI Jacek L. PILARSKI Radosław ORZAEZ Mar PINEDA-LUCENA Antonio LARAIA Luca NAMI Faranak ZIELENKIEWICZ Piotr PARUCH Kamil HANSEN Espen VON KRIES Jens P. NEUENSCHWANDER Martin SPECKER Edgar BARTŮNĚK Petr SIMOVA Šárka LESNIKOWSKI Zbigniew KRAUSS Stefan LEHTIO Lari BILITEWSKI Ursula BRONSTRUP Mark TASKEN Kjetil JIRGENSONS Aigars LICKERT Heiko CLAUSEN Mads H. ANDERSEN Jeanette H. VICENT Maria J. GENILLOUD Olga MARTINEZ Aurora NAZARE Marc FECKE Wolfgang GRIBBON Philip

Year of publication 2019
Type Article in Periodical
Magazine / Source SLAS DISCOVERY
MU Faculty or unit

Faculty of Science

Citation
Web Full Text
Doi http://dx.doi.org/10.1177/2472555218816276
Keywords chemical biology; screening; medicinal chemistry; open access; compound library
Description Compound screening in biological assays and subsequent optimization of hits is indispensable for the development of new molecular research tools and drug candidates. To facilitate such discoveries, the European Research Infrastructure EU-OPENSCREEN was founded recently with the support of its member countries and the European Commission. Its distributed character harnesses complementary knowledge, expertise, and instrumentation in the discipline of chemical biology from 20 European partners, and its open working model ensures that academia and industry can readily access EU-OPENSCREEN's compound collection, equipment, and generated data. To demonstrate the power of this collaborative approach, this perspective article highlights recent projects from EU-OPENSCREEN partner institutions. These studies yielded (1) 2-aminoquinazolin-4(3H)-ones as potential lead structures for new antimalarial drugs, (2) a novel lipodepsipeptide specifically inducing apoptosis in cells deficient for the pVHL tumor suppressor, (3) small-molecule-based ROCK inhibitors that induce definitive endoderm formation and can potentially be used for regenerative medicine, (4) potential pharmacological chaperones for inborn errors of metabolism and a familiar form of acute myeloid leukemia (AML), and (5) novel tankyrase inhibitors that entered a lead-to-candidate program. Collectively, these findings highlight the benefits of small-molecule screening, the plethora of assay designs, and the close connection between screening and medicinal chemistry within EU-OPENSCREEN.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info